Objective: To study the effects of Ginkgo biloba capsule combined with flunarizine hydrochloride on intracranial arterial hemodynamics and serum levels of β-endorphin (β-EP), 5-hydroxytryptamine (5-HT) and calcitonin gene-related peptide (CGRP) in patients with migraine. Methods: 100 migraine patients admitted to the hospital from January 2021 to December 2022 were selected as the study objects. Ginkgo biloba group (n=50) and reference group (n=50) were randomly divided by computer numbering method. Reference group was treated with flunarizine hydrochloride, and ginkgo biloba capsule was added to the reference group. The efficacy, clinical symptoms, intracranial arterial hemodynamics, serum β-EP, 5-HT and CGRP levels were compared between the two groups. Results: The total effective rate of ginkgo biloba group was higher than that of reference group (94.00% vs 78.00%) (P < 0.05). After 3 months of treatment, headache frequency, duration and headache intensity scores in both groups were lower than before treatment, and those in ginkgo biloba group were lower than those in reference group (all P < 0.05). After 3 months of treatment, the levels of intracranial arterial hemodynamics indexes in both groups were lower than before treatment, and those in ginkgo biloba group were lower than those in reference group (all P < 0.05). After 3 months of treatment, the levels of serum β-EP, 5-HT and CGRP in both groups were improved compared with those before treatment, and the improvement degree in ginkgo biloba group was better than that in reference group (all P < 0.05). Conclusion: Ginkgo leaf capsule combined with flunarizine hydrochloride has a good effect in the treatment of migraine patients, and can improve intracranial arterial hemodynamics and serum β-EP, 5-HT, CGRP levels, which is worthy of promotion and application.